Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Cancer Res. 2017 Feb 24;77(9):2266–2278. doi: 10.1158/0008-5472.CAN-16-2310

Figure 7. Heterogeneous loss of CCL2, the CCR2 ligand, extends survival of glioblastoma bearing mice.

Figure 7

(A) Survival curve of GBM patients stratified according to their CCL2 expression queried from the TCGA databank. (B) Diagram illustrating the generation of tumors in Ccl2+/− mice using RCAS/Ntva system. (C) Survival curve of tumor-bearing Ntva+ mice. N is denoted in the figures. * P<0.05 by Mantel-Cox test.